PVCT
Provectus Biopharmaceuticals, Inc.
$0.07
0.00 (-2.90%)
At close · Jul 7
Market Cap
$28.16M
Shares
420,279,879
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.07
Open$0.07
Day$0.07–0.07
52W$0.04–0.11
Avg vol 30d122K
Short int803K · 0.2% float · 4.4d
Short vol70%
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
+4%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+8%
trailing
YTD return
+20%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +41110.7% MoM · 4.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
6 holders — mid 4-yr range
Squeeze score
43
elevated · 0–100
Fundamentals
EPS growth
0%
Y/Y
Free cash flow
$-3.4M
Balance sheet
$251.3K
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +41110.7% MoM · 4.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
6 holders — mid 4-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 43%
52-wk high $0
vs 200-day avg +9%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PVCT
this stock
Provectus Biopharmaceuticals, Inc.
|
$28.16M | +19.6% | -45.5% | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
6
- % held
- 0.0%
- Net QoQ
- +19.6K sh
- Top holder
- HOME FEDERAL BANK OF TENN…
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PVCT | +0.0% | +6.4% | +8.1% | -2.9% | +19.6% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -0.9% | +5.0% | +0.5% | -3.0% | +10.0% |